SI2546233T1 - HYDROBENZAMIDE DERIVATIVES AS FRAUDING HSP90 - Google Patents
HYDROBENZAMIDE DERIVATIVES AS FRAUDING HSP90 Download PDFInfo
- Publication number
- SI2546233T1 SI2546233T1 SI200732010T SI200732010T SI2546233T1 SI 2546233 T1 SI2546233 T1 SI 2546233T1 SI 200732010 T SI200732010 T SI 200732010T SI 200732010 T SI200732010 T SI 200732010T SI 2546233 T1 SI2546233 T1 SI 2546233T1
- Authority
- SI
- Slovenia
- Prior art keywords
- therapeutic agents
- combination
- lactate salt
- agents
- combination according
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 3
- VUYRFIIFTJICNA-LKNRODPVSA-N (e)-n-[[(e)-benzylideneamino]-phenylmethyl]-1-phenylmethanimine Chemical class C=1C=CC=CC=1/C=N/C(C=1C=CC=CC=1)\N=C\C1=CC=CC=C1 VUYRFIIFTJICNA-LKNRODPVSA-N 0.000 title claims 2
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 239000002253 acid Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 150000003893 lactate salts Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 108010077544 Chromatin Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 150000003895 L-lactate salts Chemical group 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 238000005054 agglomeration Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000003388 anti-hormonal effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000003483 chromatin Anatomy 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940043274 prophylactic drug Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82924306P | 2006-10-12 | 2006-10-12 | |
| GBGB0620259.2A GB0620259D0 (en) | 2006-10-12 | 2006-10-12 | Pharmaceutical compounds |
| EP12187611.4A EP2546233B1 (en) | 2006-10-12 | 2007-10-12 | Hydrobenzamide derivatives as inhibitors of hsp90 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2546233T1 true SI2546233T1 (en) | 2018-04-30 |
Family
ID=37491396
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731206T SI2081895T1 (sl) | 2006-10-12 | 2007-10-12 | Derivati hidrobenzamida kot zaviralci HSP90 |
| SI200732010T SI2546233T1 (en) | 2006-10-12 | 2007-10-12 | HYDROBENZAMIDE DERIVATIVES AS FRAUDING HSP90 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200731206T SI2081895T1 (sl) | 2006-10-12 | 2007-10-12 | Derivati hidrobenzamida kot zaviralci HSP90 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8653084B2 (enExample) |
| EP (2) | EP2546233B1 (enExample) |
| JP (1) | JP5726416B2 (enExample) |
| KR (1) | KR101571568B1 (enExample) |
| CN (1) | CN101848892B (enExample) |
| AU (1) | AU2007306104B2 (enExample) |
| BR (1) | BRPI0719879A8 (enExample) |
| CA (1) | CA2665931C (enExample) |
| CY (2) | CY1113873T1 (enExample) |
| DK (2) | DK2081895T3 (enExample) |
| ES (2) | ES2402903T3 (enExample) |
| GB (1) | GB0620259D0 (enExample) |
| HR (2) | HRP20130255T1 (enExample) |
| HU (1) | HUE037268T2 (enExample) |
| IL (1) | IL197934A (enExample) |
| LT (1) | LT2546233T (enExample) |
| ME (1) | ME01874B (enExample) |
| MX (1) | MX2009003739A (enExample) |
| NO (1) | NO342242B1 (enExample) |
| NZ (1) | NZ576110A (enExample) |
| PL (2) | PL2546233T3 (enExample) |
| PT (2) | PT2546233T (enExample) |
| RS (2) | RS57079B1 (enExample) |
| RU (1) | RU2490258C2 (enExample) |
| SI (2) | SI2081895T1 (enExample) |
| TW (1) | TWI429638B (enExample) |
| WO (1) | WO2008044034A1 (enExample) |
| ZA (1) | ZA200902270B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2523565T3 (es) | 2005-04-13 | 2014-11-27 | Astex Therapeutics Limited | Derivados de hidroxibenzamida y sus usos como inhibidores de la hsp90 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8779132B2 (en) * | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9096518B2 (en) | 2009-06-22 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| DK2812341T3 (da) * | 2012-02-09 | 2019-11-18 | Univ Kansas | C-terminale hsp90-inhibitorer |
| CN104812898B (zh) * | 2012-05-25 | 2018-01-30 | 博格有限责任公司 | 通过调节热休克蛋白质(HSP)90‑β治疗代谢综合征的方法 |
| EP3119398A1 (en) | 2014-03-20 | 2017-01-25 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical formulation comprising a substitued phenyl- (1, 3-dihydro-isoindol-2-yl) -methanone |
| WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| AU2021211925A1 (en) * | 2020-01-20 | 2022-08-25 | Neophore Limited | Isoindoline derivatives which bind to an ATP binding site |
| CN114767683A (zh) * | 2022-04-29 | 2022-07-22 | 暨南大学 | Onalespib在制备预防和/或治疗腺病毒感染的药物中的应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5540563Y2 (enExample) | 1972-04-26 | 1980-09-22 | ||
| JPS4910506A (enExample) | 1972-05-31 | 1974-01-30 | ||
| US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| CA1340191C (en) | 1988-06-13 | 1998-12-15 | Katsuhiro Imaki | Derivatives of p-substituted phenyl ester of pivalic acid |
| US4990511A (en) | 1988-08-03 | 1991-02-05 | Takeda Chemical Industries, Ltd. | Amide compounds, their production and use |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5124350A (en) * | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| CA2049481A1 (en) | 1990-08-27 | 1992-02-28 | Jill Ann Panetta | Method of treating inflammatory bowel disease |
| FR2669029B1 (fr) | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5280046A (en) | 1991-02-22 | 1994-01-18 | The University Of Colorado Foundation, Inc. | Method of treating type I diabetes |
| WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
| US5619092A (en) * | 1993-02-01 | 1997-04-08 | Motorola | Enhanced electron emitter |
| US5633283A (en) | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
| JPH0910506A (ja) | 1995-06-30 | 1997-01-14 | Toshiba Corp | 脱気器 |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| JP3855026B2 (ja) | 1996-01-16 | 2006-12-06 | 富士レビオ株式会社 | アミド誘導体の製造方法 |
| EP0883403B1 (en) | 1996-01-29 | 2010-08-25 | The Regents of The University of California | Method for treating sexual dysfunctions |
| GB9606187D0 (en) | 1996-03-23 | 1996-05-29 | Inst Of Food Research | Production of vanillin |
| AU715658B2 (en) | 1996-04-03 | 2000-02-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2250856A1 (en) | 1996-04-19 | 1997-10-30 | The Regents Of The University Of California | Treatment of mood/affective disorders by glutamatergic upmodulators |
| IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO1998040385A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| BR9814106A (pt) | 1997-10-27 | 2000-10-03 | Cortex Pharma Inc | Processo para tratar da esquizofrenia em um indivìduo, e, conjunto |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| EP1165492A1 (en) | 1999-03-30 | 2002-01-02 | Pharmacor Inc. | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| DE19955283A1 (de) | 1999-11-17 | 2001-05-23 | Aventis Res & Tech Gmbh & Co | Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren |
| US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| WO2001060369A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| ATE310728T1 (de) * | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| DE10024939A1 (de) | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| BR0113520A (pt) | 2000-08-25 | 2003-06-24 | Warner Lambert Co | Processo de preparação de ácidos n-aril-antranìlicos e seus derivados |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| AU2002366362A1 (en) | 2001-12-18 | 2003-06-30 | Bayer Aktiengesellschaft | 2-substituted pyrrolo(2.1-a)isoquinolines against cancer |
| BR0215202A (pt) | 2001-12-20 | 2004-10-13 | Osi Pharm Inc | Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| US20030203915A1 (en) | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
| TWI280876B (en) * | 2002-06-05 | 2007-05-11 | Inst Med Molecular Design Inc | Therapeutic drug for diabetes |
| CA2487891A1 (en) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
| AU2003242131A1 (en) | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
| CN1658872B (zh) | 2002-06-06 | 2010-09-22 | 株式会社医药分子设计研究所 | 抗过敏药 |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| AU2003255711B2 (en) | 2002-07-16 | 2008-11-13 | Amura Therapeutics Limited | Biologically active compounds |
| WO2004035571A1 (en) | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| TWI228885B (en) | 2003-01-23 | 2005-03-01 | Mediatek Inc | Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode |
| SI1611112T1 (sl) | 2003-02-11 | 2012-12-31 | Vernalis (R&D) Limited | Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov |
| JP2006514088A (ja) * | 2003-02-20 | 2006-04-27 | ユニバーシティー オブ コネティカット ヘルス センター | 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法 |
| WO2004074283A1 (en) | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｊｎｋ阻害剤 |
| BRPI0409977A (pt) | 2003-04-30 | 2006-05-09 | Novartis Ag | derivados de aminopropanol como moduladores de receptores esfingosina-1-fosfato |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| CA2530374C (en) | 2003-06-27 | 2012-05-15 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
| TWI312345B (en) | 2003-06-30 | 2009-07-21 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
| CN100406006C (zh) * | 2003-07-16 | 2008-07-30 | 株式会社医药分子设计研究所 | 皮肤色素沉着的治疗剂 |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| WO2005009940A1 (en) | 2003-07-24 | 2005-02-03 | Leo Pharma A/S | Novel aminobenzophenone compounds |
| CN100591679C (zh) | 2003-07-28 | 2010-02-24 | 詹森药业有限公司 | 苯并咪唑、苯并噻唑和苯并唑衍生物及其作为lta4h调节剂的应用 |
| DE10335584B4 (de) * | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Verfahren zur Herstellung zyklischer Moleküle |
| DE10335726A1 (de) * | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
| WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| OA13315A (en) | 2003-10-14 | 2007-04-13 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
| JP2007513082A (ja) | 2003-11-10 | 2007-05-24 | シエーリング アクチエンゲゼルシャフト | Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物 |
| WO2005063222A1 (ja) | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| US7351709B2 (en) * | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| AU2005277223C1 (en) | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| US7208630B2 (en) * | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| EP1813270A4 (en) * | 2004-11-09 | 2009-07-01 | Kyowa Hakko Kirin Co Ltd | PROTEIN INHIBITORS OF THE HSP90 FAMILY |
| PT1817295E (pt) * | 2004-11-18 | 2013-02-18 | Synta Pharmaceuticals Corp | Compostos de triazol que modulam a actividade da hsp90 |
| TWI427077B (zh) | 2004-12-30 | 2014-02-21 | Astex Therapeutics Ltd | 吡唑化合物及其用途和含有彼之藥學組成物 |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| DK1848694T3 (da) | 2005-02-07 | 2010-01-25 | Hoffmann La Roche | Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter |
| US20060183902A1 (en) * | 2005-02-15 | 2006-08-17 | Baxter Ellen W | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| US20090042883A1 (en) | 2005-02-21 | 2009-02-12 | Kyowa Hakkokogyo Co. | Antitumor agent |
| ES2523565T3 (es) * | 2005-04-13 | 2014-11-27 | Astex Therapeutics Limited | Derivados de hidroxibenzamida y sus usos como inhibidores de la hsp90 |
| US20090215742A1 (en) * | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
| ES2530780T3 (es) | 2005-05-17 | 2015-03-05 | Sarcode Bioscience Inc | Composiciones y métodos para el tratamiento de trastornos oculares |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| PT1808634E (pt) * | 2006-01-12 | 2008-12-11 | Ondal Holding Gmbh | Acessório de fixação para suportar um dispositivo |
| US7754725B2 (en) * | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8916552B2 (en) * | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8779132B2 (en) * | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US8883790B2 (en) * | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
-
2006
- 2006-10-12 GB GBGB0620259.2A patent/GB0620259D0/en not_active Ceased
-
2007
- 2007-10-11 TW TW096138174A patent/TWI429638B/zh not_active IP Right Cessation
- 2007-10-12 PT PT121876114T patent/PT2546233T/pt unknown
- 2007-10-12 ES ES07824125T patent/ES2402903T3/es active Active
- 2007-10-12 WO PCT/GB2007/003871 patent/WO2008044034A1/en not_active Ceased
- 2007-10-12 RS RS20180350A patent/RS57079B1/sr unknown
- 2007-10-12 AU AU2007306104A patent/AU2007306104B2/en not_active Ceased
- 2007-10-12 RS RS20130118A patent/RS52716B/sr unknown
- 2007-10-12 CA CA2665931A patent/CA2665931C/en not_active Expired - Fee Related
- 2007-10-12 RU RU2009117589/04A patent/RU2490258C2/ru not_active IP Right Cessation
- 2007-10-12 SI SI200731206T patent/SI2081895T1/sl unknown
- 2007-10-12 PT PT78241254T patent/PT2081895E/pt unknown
- 2007-10-12 JP JP2009531915A patent/JP5726416B2/ja active Active
- 2007-10-12 CN CN2007800455503A patent/CN101848892B/zh not_active Expired - Fee Related
- 2007-10-12 PL PL12187611T patent/PL2546233T3/pl unknown
- 2007-10-12 NZ NZ576110A patent/NZ576110A/en not_active IP Right Cessation
- 2007-10-12 HU HUE12187611A patent/HUE037268T2/hu unknown
- 2007-10-12 HR HRP20130255TT patent/HRP20130255T1/hr unknown
- 2007-10-12 SI SI200732010T patent/SI2546233T1/en unknown
- 2007-10-12 KR KR1020097009666A patent/KR101571568B1/ko not_active Expired - Fee Related
- 2007-10-12 LT LTEP12187611.4T patent/LT2546233T/lt unknown
- 2007-10-12 DK DK07824125.4T patent/DK2081895T3/da active
- 2007-10-12 ES ES12187611.4T patent/ES2662359T3/es active Active
- 2007-10-12 MX MX2009003739A patent/MX2009003739A/es active IP Right Grant
- 2007-10-12 BR BRPI0719879A patent/BRPI0719879A8/pt not_active Application Discontinuation
- 2007-10-12 ME MEP-2013-34A patent/ME01874B/me unknown
- 2007-10-12 PL PL07824125T patent/PL2081895T3/pl unknown
- 2007-10-12 US US12/445,130 patent/US8653084B2/en not_active Expired - Fee Related
- 2007-10-12 EP EP12187611.4A patent/EP2546233B1/en active Active
- 2007-10-12 EP EP07824125A patent/EP2081895B1/en active Active
- 2007-10-12 DK DK12187611.4T patent/DK2546233T3/en active
-
2009
- 2009-04-01 ZA ZA2009/02270A patent/ZA200902270B/en unknown
- 2009-04-05 IL IL197934A patent/IL197934A/en active IP Right Grant
- 2009-05-12 NO NO20091858A patent/NO342242B1/no not_active IP Right Cessation
-
2013
- 2013-04-03 CY CY20131100278T patent/CY1113873T1/el unknown
-
2014
- 2014-01-07 US US14/149,450 patent/US9428439B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 HR HRP20180375TT patent/HRP20180375T1/hr unknown
- 2018-03-19 CY CY20181100318T patent/CY1120081T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2546233T1 (en) | HYDROBENZAMIDE DERIVATIVES AS FRAUDING HSP90 | |
| US11957657B2 (en) | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | |
| BR0314577A (pt) | Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) | |
| US11471503B2 (en) | Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain | |
| BRPI0407999A (pt) | compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf) | |
| US20200054594A1 (en) | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof | |
| BR0314372A (pt) | Compostos imidazol como inibidores do fator de crescimento tranformador (tgf) | |
| RS52274B2 (sr) | Jedinjenje diarilhidantoina | |
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| CA2701649A1 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| CA3157998A1 (en) | Conjugate molecules | |
| US20230372372A1 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
| JP7373571B2 (ja) | がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン | |
| US20130338372A1 (en) | Substituted Imidazoline Compounds | |
| WO2019082124A1 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| CA3028122A1 (en) | Porphyrin compounds and compositions useful for treating cancer | |
| RU2005105693A (ru) | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний | |
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| US11559537B2 (en) | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | |
| JP2021501160A (ja) | 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター | |
| BR112023027454A2 (pt) | Composto, uso de um composto, medicamento, e, invenção de produto, processo, sistema, kit ou uso | |
| TWI423800B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療顱部創傷的藥物之用途 | |
| JP6760657B2 (ja) | タイトジャンクションの緩和剤、該緩和剤を含む薬剤吸収補助剤、及び該緩和剤を含む医薬組成物 |